![A 36-year-old woman with a diagnosis of a left popliteal synovial sarcoma treated with surgery and chemotherapy (adryamicin/ifosfamide). A local recurrence required additional surgery followed by chemoradiotherapy (70 Gy plus ifosfamide). She had a disease-free interval of 4 years until lung metastasis was detected. Between October 2007 and May 2012, she was treated with several drug combinations (in total, she had been resistant to \>6 lines of therapy including all the available active drugs in soft tissue sarcomas) and operated by thoracotomy in 3 stages. Pazopanib treatment was initiated in November 2012 and then interrupted because of hemoptysis. She was referred to our institution in February 2013 presenting extreme weight loss and a performance status of 2. The most recent scan showed lung metastasis in more than 50% of the right side of the thorax, with large pleural disease and mediastinum involvement. Traqueal compression at carina level was present. A computed tomography--guided needle biopsy from a lung metastatic lesion was performed for an expression microarray. A highly significant expression of the somatostatin receptor 2 (SSTR2) gene (in excess of 10-fold) and to a lesser extent SSTR5 (\>5-fold) as compared with the normal control tissue was apparent in the normalized microarray data. There are references in literature identifying SSTR in more than 80% of the soft tissue tumors analyzed by reverse transcriptase--polymerase chain reaction,^[@bib1],[@bib2]^ as well as positive uptake in molecular imaging.^[@bib3],[@bib4]^ Figure 1 shows the high uptake in the right hemithorax in the Octreoscan confirming the potential indication for somatostatin analog--based treatments. She began lanreotide 30 mg intramuscularly every 2 to 3 weeks until May 31, 2013, reaching disease stabilization.](rlu-41-705-g001){#FU1}

![She underwent 2 cycles with Lutathera, a radiolabeled somatostatin analog that has been shown to be an effective and safe treatment for somatostatin receptor--positive gastroenteropancreatic neuroendocrine tumors^[@bib5]--[@bib7]^: 5.55 GBq in July 2013 and 7.4 GBq in September 2013. Figure 2 shows posttherapy ^177^Lu-octreotate whole-body scans (**A**, first course, July 2013; **B**, second course, September 2013). A superior uptake than the baseline Octreoscan can be shown in the first ^177^Lu-octreotate scan and additionally 2 implants upon the chest wall and a new local recurrence of the primary lesion in the left knee. Tolerance was excellent as it has been previously reported.^[@bib8],[@bib9]^ After the first cycle, 1 episode of hemoptysis was observed, without any hematologic disturbance, and resolved with symptomatic medication. The patient had a very important clinical improvement from the beginning of the treatment, better quality of life, performance status, and daily life activities. In addition, a significant reduction of lung masses can be shown by comparison of both ^177^Lu-octreotate scan after the first single course.](rlu-41-705-g002){#FU2}

![Objective partial response based on RECIST criteria (reduction of \>50%) was observed after 2 courses of Lutathera. Figure 3 shows baseline thoracic computed tomography scan (**A--C**) and after 11 months (**D--F**). The overall duration of her response (stabilization with cold lanreotide and partial response with Lutathera) exceeded 1 year. The objective reduction made possible a surgical approach in an attempt to reduce the tumor load, and therefore a thoracotomy and debulking was carried out in January 2014. Unfortunately, an accidental rupture of the right atrium with profuse bleeding occurred during surgery. She died in April 2014 after a long stay in the intensive care unit. Lutathera is an investigational medical product in late-stage development.](rlu-41-705-g003){#FU3}
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